Phosphoinositide 3-kinase inhibitor with a zinc binding moiety

Inventors

Cai, Xiong • Zhai, Haixiao • Lai, Chengjung • Qian, Chenggeng

Assignees

Curis Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10111864-B2

Patent

Publication Date

2018-10-30

Expiration Date


Abstract

The invention provides a compound of Formula I,Pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.

Core Innovation

The document describes phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC) dual-inhibitor compounds, including Compound 1 (Formula I) and pharmaceutically acceptable salts. The compounds include zinc-binding moieties intended to mediate HDAC inhibition, and the document places the activity within PI3K/HDAC related disease contexts, especially cancers.

The problem described in the background is the need for improved therapeutic agents for PI3K- and/or HDAC-related diseases, with particular emphasis on cancer treatment. The document contrasts dual inhibition via a single molecule against strategies using separate inhibitors, aiming to achieve combined PI3K and HDAC pathway modulation.

For Compound 1, the document reports properties including potent PI3K and HDAC inhibition and antiproliferative effects in vitro. It also reports oral bioavailability and tumor uptake with pharmacodynamic activity in xenograft tumor-bearing mice after oral and intravenous dosing, alongside substantial antitumor activity and acceptable safety in Ames genotoxicity testing.

Claims Coverage

The provided claim set includes two independent claims: one independent method claim directed to producing Compound 1 from a specified intermediate, and one independent chemical formula claim defining a compound where a substituent R is ethyl or methyl. Together, the inventive features center on a specific precursor-to-Compound 1 transformation and a generic chemical formula with R limited to methyl or ethyl.

Producing compound 1 from compound 108 by hydroxylamine reaction

A method comprising reacting Compound 108, wherein R is methyl or ethyl, with hydroxylamine thereby producing Compound 1.

Compound defined by formula with r limited to methyl or ethyl

A compound of the formula wherein R is ethyl or methyl.

The independent claims cover a specific route to Compound 1 by reacting Compound 108 with hydroxylamine, and a chemical formula definition of the compound where the substituent R is limited to ethyl or methyl.

Stated Advantages

Potent PI3K and HDAC inhibition.

Antiproliferative effects in vitro.

Oral bioavailability.

Tumor uptake and pharmacodynamic activity in xenograft models after oral/IV dosing.

Substantial antitumor activity.

Acceptable safety in Ames genotoxicity testing.

Documented Applications

Treating PI3K- and/or HDAC-related diseases, especially cancers, using PI3K/HDAC dual-inhibitor compounds including Compound 1.

Combination-therapy examples are described in the context of the therapeutic use of the compounds.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.